Reported value$533K20,000 shares at $26.63
For this personUnusual1 buy · 0 sales on file
Similar buys beat S&P52%110 cases · all buys 46%
Worth a closer look
- Open-market purchase with their own money (Form 4 code P), not a grant or option exercise.
- Raised their own holding by 747%.
- Similar past buys beat the S&P 500 52% of the time (110 cases), above the 46% for all buys.
Reasons for caution
- None found in the data.
What happened after this filing
7 days
Pending
due Nov 2
30 days
Pending
due Nov 25
90 days
Pending
due Jan 24
Insider Twins: past buys with the same traits
2 insiders buying · incl. CEO or CFO · $250K–$1M · stock down 20%+ in 3 months
BCAB Jun 23, 2022 +189.1% vs S&PFCNCA Mar 13, 2023 +106.4% vs S&PPFSI Mar 20, 2020 +98.6% vs S&PMYO May 15, 2025 -77.0% vs S&PMITT Mar 12, 2020 -68.1% vs S&PANDE Mar 18, 2020 -55.5% vs S&PWhat we couldn't check
- Why they traded. Filings don't say, and we don't guess.
- Company news after the filing, and any private terms.
Summary
Paul Anthony Mascarenas (a director) bought $533K of THRM at about $26.63 on Oct 23, 2026, reported to the SEC on Oct 26, 2026. Buys like this beat the S&P 500 52% of the time since 2020, against 46% for all insider buys. We found 3 points that make it worth a closer look and 0 reasons for caution. History, not a prediction.
Following. We'll keep this page updated; see everything you follow. Want an email when the 30 and 90-day results land? Use the THRM alerts below.
Written by fixed rules from SEC filings and our measured history, not by an AI model. Public data only. History, not a prediction, and not investment advice.